"Noramco’s President and CEO, James Mish, signed on in July of 2016 to transform the now independent specialty API company into a business that delivers extra value. “We are transforming the business to deliver extra value in three ways: through commercial excellence, meaning bringing up our standard of customer service, not just as an API maker but also as a full solution provider; new operational excellence, making sure we operate our assets more efficiently; and, strategic growth,” Mish said. To grow the business, Mish is moving forward with global API registrations that began years ago to make Noramco’s portfolio of specialty APIs accessible to pharmaceutical product makers in additional markets. He also plans to accelerate growth by expanding the company’s portfolio of controlled APIs. Since taking the helm of Noramco, he has accelerated Noramco’s API innovation pipeline, moving five products forward to full development in just 5 months. “We moved forward with five product initiatives, including new additions to the amphetamines family, the addition of methylphenidate and hydrocodone base APIs, and a new cannabinoid partnership with Teewinot Life Sciences.” Moreover, Mish is applying a ”solution” model to drive extra value for customers and add value beyond typical supplier-customer opportunities."

biomedical devices